AB Science S.A Asset Resilience Ratio
AB Science S.A asset resilience ratio. AB Science S.A (AB) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of AB Science S.A to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of AB Science S.A (2009–2024)
Asset resilience ratio of AB Science S.A from 2009 to 2024. This chart shows how AB Science S.A's Asset Resilience Ratio has changed over time. Read AB current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down AB Science S.A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is AB Science S.A's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €1.00K | 0.0% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €1.00K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: AB Science S.A maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
AB Science S.A Industry Peers by Asset Resilience Ratio
Compare AB Science S.A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
AB Science S.A Asset Resilience Ratio by Year (2009–2024)
AB Science S.A asset resilience ratio by year from 2009 to 2024. The table below shows the annual Asset Resilience Ratio data for AB Science S.A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | €0.00 ≈ $0.00 |
€23.18 Million ≈ $27.09 Million |
-- |
| 2022-12-31 | 0.00% | €0.00 ≈ $0.00 |
€23.84 Million ≈ $27.87 Million |
-- |
| 2021-12-31 | 0.00% | €0.00 ≈ $0.00 |
€21.27 Million ≈ $24.87 Million |
-- |
| 2020-12-31 | 0.00% | €0.00 ≈ $0.00 |
€29.69 Million ≈ $34.71 Million |
-- |
| 2019-12-31 | 0.00% | €0.00 ≈ $0.00 |
€17.74 Million ≈ $20.74 Million |
-- |
| 2018-12-31 | 26.68% | €6.00 Million ≈ $7.02 Million |
€22.49 Million ≈ $26.29 Million |
+6.92pp |
| 2017-12-31 | 19.76% | €10.00 Million ≈ $11.69 Million |
€50.60 Million ≈ $59.16 Million |
+19.77pp |
| 2016-12-31 | 0.00% | €-1.00K ≈ $-1.17K |
€38.01 Million ≈ $44.44 Million |
-18.44pp |
| 2015-12-31 | 18.44% | €6.01 Million ≈ $7.02 Million |
€32.58 Million ≈ $38.09 Million |
-0.62pp |
| 2014-12-31 | 19.06% | €5.96 Million ≈ $6.97 Million |
€31.28 Million ≈ $36.56 Million |
+8.73pp |
| 2013-12-31 | 10.32% | €4.50 Million ≈ $5.27 Million |
€43.63 Million ≈ $51.01 Million |
-28.72pp |
| 2012-12-31 | 39.04% | €11.71 Million ≈ $13.69 Million |
€29.98 Million ≈ $35.05 Million |
+10.00pp |
| 2011-12-31 | 29.05% | €8.56 Million ≈ $10.01 Million |
€29.46 Million ≈ $34.44 Million |
-29.47pp |
| 2010-12-31 | 58.52% | €17.20 Million ≈ $20.11 Million |
€29.40 Million ≈ $34.37 Million |
+33.63pp |
| 2009-12-31 | 24.89% | €3.51 Million ≈ $4.10 Million |
€14.09 Million ≈ $16.47 Million |
-- |
About AB Science S.A
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyo… Read more